LONDON, August 10, 2026, 19:34 BST — U.S. trading continued as normal.
- The UK is the first country in Europe to approve Foundayo, a tablet produced by Eli Lilly and Company NYSE:LLY.
- Eli Lilly was quoted around $1,220, rising roughly 2.9%, at 14:19 EDT.
- Foundayo reported $98 million in sales for the second quarter, with NHS access still awaiting approval.
Eli Lilly and Company’s NYSE:LLY Foundayo received approval in Britain for weight management and type 2 diabetes on Monday. Shares last traded at approximately $1,220, up 2.9%, as of 14:19 EDT, valuing the company near $1.09 trillion.
The approval allows use in the UK, but does not grant EU authorisation or guarantee NHS availability. Lilly has yet to announce a UK price or launch date, leaving the timeline for private-market availability unclear.
Based on the approximately $1.09 trillion value after the move, calculating $1.09 trillion × 2.9/102.9 results in an estimated $30.7 billion increase. Foundayo reported $98 million for the second quarter. This means the rise in equity value was around 313 times the pill’s sales for that quarter.
| Valuation measure | Verified value or calculation | Investor read |
|---|---|---|
| Lilly’s market capitalization at the quote | About $1.09 trillion | Mega-cap sized |
| Market cap increase on Monday | About $30.7 billion | Reflects 2.9% change in shares |
| Foundayo second-quarter revenue | $98 million | First quarter since launch |
| Monday’s gain as a multiple of Foundayo Q2 revenue | About 313x | Measured for scale, not as a direct link |
| Foundayo portion of Lilly Q2 revenue | 0.43% | $98 million versus $22.974 billion |
The comparison shows the difference between existing pill revenue and the change in equity value seen on the day; it does not prove that the UK outcome directly led to the stock move. Market value figures use the listed price; revenue data is based on Lilly’s August 5 report.
Foundayo is still modest in scale compared to Lilly’s injectable lineup. Mounjaro brought in $9.943 billion in Q2 sales and Zepbound accounted for $4.928 billion. Lilly’s overall revenue for the quarter was $22.974 billion, marking a 48% year-over-year increase.
| Lilly measure | Q2 2026 or current guidance | Comparison |
|---|---|---|
| Total revenue | $22.974 billion | Rose 48% from a year earlier |
| Mounjaro revenue | $9.943 billion | Increased 91% year-over-year |
| Zepbound revenue | $4.928 billion | Gained 46% compared to last year |
| Foundayo revenue | $98 million | New launch; no year-ago figure |
| 2026 revenue guidance | $85 billion–$87 billion | Updated from previous range of $82 billion–$85 billion |
The Medicines and Healthcare products Regulatory Agency has granted approval to Foundayo for the treatment of obesity in adults. Authorization also extends to overweight adults who have an associated health condition, as well as those with type 2 diabetes that is not adequately controlled.
| UK authorisation item | Position on August 10 |
|---|---|
| Weight-management threshold | BMI of 30 or higher |
| Additional eligible group | BMI of 27–30 in addition to at least one weight-related condition |
| Type 2 diabetes | Permitted for cases not sufficiently managed |
| Dosing | Administered daily; dose starts at 0.8 mg and increases up to 17.2 mg |
| Food and water restrictions | No restrictions |
| NHS availability | Currently unavailable |
| Expected NICE publication | November 18, 2026 |
Julian Beach, executive director for healthcare quality and access at the MHRA, stated, “we are pleased to be the first regulator in Europe to authorise this tablet.” The agency plans to continue monitoring its safety and efficacy. MHRA decision and quote
NHS access now represents the closest commercial threshold. The NICE appraisal, anticipated on November 18, will decide if NHS use is advised and for which patients. Even with a positive outcome, questions over rollout timing and commercial terms could remain.
Novo Nordisk A/S NYSE:NVO currently holds a lead with its oral Wegovy. In its second-quarter update on August 5, using data from July, the company reported that approximately 300,000 patients in the UK had taken the pill within three weeks. Novo also projected around 1.5 million users worldwide.
| UK oral-obesity market indicator | Novo Nordisk estimate |
|---|---|
| Number of UK adults with obesity | About 20 million |
| Individuals receiving treatment ahead of Wegovy pill debut | About 1.6 million |
| Projected Wegovy pill users within three weeks of UK release | About 300,000 |
| Projected worldwide users of Wegovy pill | About 1.5 million |
| Top 20 providers’ share of UK private obesity sector | More than 75% |
These figures come from Novo’s projections and are not verified national patient totals. Nevertheless, they illustrate the scale of the issue. If Lilly opts for a private rollout, Foundayo will face a focused sector in which its key competitor already enjoys established prescriber relationships and distribution networks.
Several Lilly price targets on Wall Street were increased last week following its results. The adjustments listed below were made before Monday’s authorisation in the UK, and should not be interpreted as responses to that event.
| Broker | Date | Recommendation | New target | Prior target |
|---|---|---|---|---|
| Truist | August 7 | Buy | $1,376 | $1,370 |
| Goldman Sachs | August 6 | Buy | $1,367 | $1,283 |
| BMO Capital | August 6 | Outperform | $1,400 | $1,300 |
| Morgan Stanley | August 6 | Overweight | $1,419 | $1,347 |
The most recent FactSet survey showed an Overweight consensus rating. The median price target came in at $1,371.50, reflecting a roughly 12% premium to Monday’s closing price. Price forecasts ranged from $850 to $1,680, highlighting broad differences among analysts.
UK pricing, launch schedule and NHS reimbursement have yet to be finalised. Novo remains ahead with its established pill. Gastrointestinal side effects and the need for post-market safety surveillance could limit adoption. A slow start in the private sector or strict NICE restrictions would reduce the European revenue outlook.
Lilly last week increased its 2026 revenue projection to a range of $85 billion–$87 billion. Chief Executive David Ricks stated, “Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance.” Foundayo’s approval in the UK provides further growth potential, but the disclosed outlook remains unchanged. Lilly Q2 results and quote
The upcoming NICE appraisal on November 18 is the next clear UK milestone. Investors are looking for details on reimbursement, a launch price, and proof that Foundayo can match Novo’s pill advantage. Lacking these, Monday’s authorisation is still primarily a significant regulatory opportunity, not yet a projected NHS revenue generator.
Related articles: NYSE:LLY
